NCT00931242 - Study of Apremilast in Atopic or Contact Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Atopic DermatitisAllergic Contact Dermatitis

Interventions

DRUG

Apremilast

Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).

Trial Locations (1)

02111

Tufts Medical Center, Department of Dermatology, Boston